The Director, Oncology Marketing is a member of the Sandoz Biopharmaceuticals US Commercial team and is responsible for commercial activities which will maximize the net sales, market share and operating income of the Sandoz Biopharmaceuticals oncology portfolio for the US. S/he will lead the development and execution of the US brand plan for Zarxio® (filgrastim-sndz) and GP2013 (rituximab biosimilar), with specific responsibility for leading the development and execution of the GP2013 launch plan. The Director, Oncology Marketing will also lead the cross-functional US/Global launch management team for GP2013. In addition the Director, Oncology Marketing will contribute to the development of specific customer level business plans in order to create profitable access and optimize sales and market share with key customers in the oncology market. Focus will be on establishing an early strategic entry point into the US market via these customers, and then driving sales and market share in order to maximize the opportunity. The Director, Oncology Marketing reports to the Executive Director, Oncology Franchise Head for Sandoz Biopharmaceuticals.
• Lead the development, execution and performance monitoring of the Zarxio (filgrastim-sndz) annual brand plan to maximize US net sales and operating income
• Lead the development and execution of the GP2013 (rituximab biosimilar) commercial launch plan and annual brand plan
o Lead the cross-functional US/Global GP2013 launch management team
o Comprehensive understanding of the CD20 MAb market including competitors, identifi-cation of brand growth opportunities and threats
o Contribute to the strategic segmentation of the US market for GP2013 (rituximab bio-similar) and identification of target customers
o Ensure successful development and execution of differentiating and compelling brand promotion for GP2013 for the US market
• Manage the overall advertising and promotion budget for the Sandoz Biopharmaceuticals oncol-ogy portfolio for the US, including prioritization of select tactics which will drive optimal brand pull through for US market
• Contribute to the development and execution of a US customer level business plan in order to maximize Zarxio and the launch of GP2013 (rituximab biosimilar) into the US oncology market
• Build and maintain solid relationships with key external oncology customers such as thought leaders, provider organizations, and other key external customers and stakeholders.
• Ensure operational excellence for product supply in the US market
• Ensure adherence and compliance to all Sandoz and Novartis policies and procedures
EEO Statement The Novartis Group of Companies are Equal Opportunity Employers and take pride in maintaining a diverse environment. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.
Minimum requirements • Bachelor's degree or equivalent in business or health-related field
• Advanced degree (e.g. MBA, MD, PharmD, etc.) pre-ferred English
• Requires at least 7 years’ total work experience in pharma/biotech/medical device with a track record of progressing to more senior roles & responsibilities
• Previous marketing experience required – minimum 5 years; product launch experience (new product launch and/or significant line extension) preferred
• Previous experience in oncology is required (minimum 5 years)
• Direct sales experience in oncology and/or account management (managed markets) experience preferred, with experience in key account management (managed markets) for Oncology providers strongly preferred o Note – experience in non-oncology therapy areas that require substantial “buy and bill” and institutional/account based selling (e.g., Immunology, some urology drugs) will be considered
• Solid understanding of the payment and reimbursement systems for oncology injectables (which can be different from oncology oral medicines), including both “buy and bill” models in private oncology practices and institutional
Send To A Friend
Posts
